Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Non Operating Income: 2021-2024

Historic Non Operating Income for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to $12.6 million.

  • Amylyx Pharmaceuticals' Non Operating Income fell 44.50% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year decrease of 49.37%. This contributed to the annual value of $12.6 million for FY2024, which is 18.72% down from last year.
  • Per Amylyx Pharmaceuticals' latest filing, its Non Operating Income stood at $12.6 million for FY2024, which was down 18.72% from $15.5 million recorded in FY2023.
  • In the past 5 years, Amylyx Pharmaceuticals' Non Operating Income registered a high of $15.5 million during FY2023, and its lowest value of -$5.2 million during FY2021.
  • For the 3-year period, Amylyx Pharmaceuticals' Non Operating Income averaged around $10.6 million, with its median value being $12.6 million (2024).
  • In the last 5 years, Amylyx Pharmaceuticals' Non Operating Income surged by 314.30% in 2023 and then declined by 18.72% in 2024.
  • Amylyx Pharmaceuticals' Non Operating Income (Yearly) stood at -$5.2 million in 2021, then soared by 171.33% to $3.7 million in 2022, then spiked by 314.30% to $15.5 million in 2023, then dropped by 18.72% to $12.6 million in 2024.